Newsletter Subject

this should be illegal

From

citizen.org

Email Address

robert@citizen.org

Sent On

Sun, Apr 7, 2024 10:42 PM

Email Preheader Text

$12.1 billion. That’s how much Big Pharma lavished on America’s doctors from 2013 to 2022,

$12.1 billion. That’s how much Big Pharma lavished on America’s doctors from 2013 to 2022, according to a new study, for things like travel, meals, drinks, honoraria, consulting, and outright gifts. - About 826,000 physicians received such payouts from drug or device makers over that ten-year span. - Some orthopedic surgeons raked in as much as $4.8 million! - But even something as seemingly innocent as a luncheon sponsored by Big Pharma has been shown to influence the decisions doctors make. - Because there’s no such thing as a free lunch. - Big Pharma knows exactly what it’s getting for investing well over a billion dollars a year — which it can easily afford due to its relentless fleecing of the American people — to influence our nation’s doctors. Multiple studies demonstrate that payments from pharmaceutical companies and device manufacturers are linked to increases in prescriptions for specific medications and the use of particular devices. That, in turn, can lead to inflated costs for patients, insurers, and Medicare. There is no reason that Big Pharma lavishing money on doctors should be legal. Congress can and must change the law so that the American people know we’re getting the medicines and devices we need rather than whatever Big Pharma happens to be influencing doctors to prescribe. [Tell Congress:]( [The American people deserve to know that we’re getting the drugs and medical devices we need, uninfluenced by payments to doctors from Big Pharma. Pass legislation to ban pharmaceutical companies and medical device manufacturers from buying influence with doctors.]( [Click to add your name now.]( Thanks for taking action. For progress, - Robert Weissman, President of Public Citizen Public Citizen | 1600 20th Street NW | Washington DC 20009 | [Unsubscribe]( [supporter]

Marketing emails from citizen.org

View More
Sent On

24/05/2024

Sent On

23/05/2024

Sent On

22/05/2024

Sent On

21/05/2024

Sent On

20/05/2024

Sent On

19/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.